Fenghua Biological
Guangzhou Fenghua Biotech is a privately held Chinese IVD company focused on birth defect prevention. It develops and manufactures clinical testing instruments based on TRFIA, tandem mass spectrometry, and colloidal gold technologies, plus over 100 matching reagents, serving hundreds of hospitals and clinical laboratories across China and select international markets.
- Company typePrivate
- Founded1999
- HeadquartersGuangzhou, China
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fenghua Biological does
Guangzhou Fenghua Biotech Co., Ltd. (广州市丰华生物股份有限公司) is a privately held Chinese in vitro diagnostics (IVD) company founded in 1999, headquartered in Guangzhou Economic & Technological Development District, with a manufacturing base spanning 3,200 sqm of land and 8,000 sqm of building area and approximately 300 employees. The company specializes in clinical testing instruments and supporting reagents, with its primary business focus on birth defect prevention through prenatal and neonatal screening — a positioning the company claims is unique among Chinese IVD firms and backed by its role as the operator of the National Birth Defects In Vitro Diagnostic System High-Tech Industrialization Demonstration Project base. Its core proprietary platform is time-resolved fluorescence immunoassay (TRFIA), with reported analytical sensitivity down to 10^-18 mol/well, complemented by HPLC, tandem mass spectrometry (via the FH-6000MD codeveloped with an unnamed Fortune 500 partner), colloidal gold immunochromatography (used in its COVID-19 product line), and molecular diagnostics capabilities. The product catalog includes the TALENT series fluorometers (TALENT-I, TALENT-II, TALENT-STAR), the AutoTRFIA automated analyzer family, the EasyDBS dry blood spot punchers, the FH-6000MD mass spectrometry system, and approximately 100 CFDA/NMPA-registered reagents plus CE-marked kits covering prenatal screening (AFP, free β-HCG, uE3, inhibin A, PAPP-A), neonatal screening (G6PD, 17-OHP, TSH/f-T4, PKU, tandem MS metabolic panels), infectious diseases (HBV, HCV, HIV, syphilis, TORCH), hepatitis B five-marker quantitative panels, and COVID-19 (IgM/IgG Combo, antigen, neutralizing antibody). Three NMPA-registered software products (prenatal risk assessment, prenatal screening information system, newborn screening information system) round out the offering.
The company operates a direct sales-led go-to-market motion targeting hospitals and clinical laboratories across 20+ Chinese provinces, supported by ~50 field service engineers organized into 8 regional zones. Revenue is generated through two primary streams: upfront instrument sales (TALENT, AutoTRFIA, EasyDBS, FH-6000MD, BW 1108 plate washer) and recurring reagent consumables tied to the installed instrument base — a closed-system, razor-and-blade model that produces predictable after-sale revenue. Pricing is quote-based and not publicly disclosed. International expansion is executed through distributor recruitment managed by the Marketing Department, with CE-certified COVID-19 kits providing a near-term entry vehicle into EU and other CE-accepting markets. The company is ISO 9001:2008 and ISO 13485:2012 certified, holds 8 invention patents, 3 utility model patents, 1 design patent, and 3 software copyrights, and has received state recognition including the National Torch Project (2005), National SME Innovation Fund Project (2008), National 863 Plan selection (2011), and various Guangdong provincial and Guangzhou municipal science and technology awards. In 2022, the company restructured from a limited liability company into a joint stock limited company (股份有限公司), a structural move that typically precedes equity financing or an IPO filing in the Chinese corporate context, though no listing or known institutional investor has been disclosed to date.
Fenghua Biological firmographics
Firmographics- Name
- Fenghua Biological
- Legal name
- GUANGZHOU FENGHUA BIOTECH CO.,LTD.
- Website
- https://bio-fenghua.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Short description
- Guangzhou Fenghua Biotech is a privately held Chinese IVD company focused on birth defect prevention. It develops and manufactures clinical testing instruments based on TRFIA, tandem mass spectrometry, and colloidal gold technologies, plus over 100 matching reagents, serving hundreds of hospitals and clinical laboratories across China and select international markets.
- Ownership category
- akta.pro rank
Fenghua Biological industry classification
Industry- Product category
- In Vitro Diagnostics (IVD)
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
- akta.pro secondary industries
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Fenghua Biological is headquartered
LocationHeadquarters
- HQ city
- Guangzhou
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Fenghua Biological business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Diagnostic Instruments and Reagents: Fenghua Biological develops, manufactures, and sells clinical diagnostic instruments (time-resolved fluorometers, mass spectrometers, dry blood spot punchers, plate washers) and matching reagent kits for prenatal screening, neonatal screening, infectious diseases, hormones, and more. Revenue is generated through direct sales of instruments and recurring reagent consumables to hospitals and clinical laboratories.
- Recurring Diagnostic Reagent Sales: After initial instrument placement, the company generates recurring revenue from the sale of配套 reagent kits covering prenatal screening, neonatal screening, TORCH, hepatitis, COVID-19, and other diagnostic panels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B instruments and reagent kits — pricing available upon inquiry |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Fenghua Biological product offering
Product offeringCore offering
Fenghua Biological develops, manufactures, and sells clinical diagnostic instruments and matching reagent kits for in vitro diagnostics, including time-resolved fluorescence immunoassay (TRFIA) analyzers, clinical mass spectrometry systems (FH-6000MD), automated dry blood spot punchers, and reagent kits for prenatal screening, neonatal screening, infectious disease testing, and hormone analysis. The portfolio is complemented by software products for prenatal and newborn screening program management and risk assessment. Customers are hospitals, maternal and child health institutions, clinical laboratories, and disease control centers across China.
Product overview
Fenghua Biological (Guangzhou Fenghua Biotech Co., Ltd.) offers an integrated in vitro diagnostic system solution focused on birth defects prevention. The product portfolio centers on time-resolved fluorescence immunoassay (TRFIA) technology and includes: (1) Instruments: FH-6000MD tandem mass spectrometry system, AutoTRFIA fully automated fluorescence immunoassay analyzer, TALENT series time-resolved fluorescence immunoassay analyzers (TALENT-I, TALENT II, TALENT-STAR), EasyDBS automated and semi-automatic dry blood spot punchers, BW 1108 microplate washer; (2) Software: Prenatal Screening Risk Assessment Software, Prenatal Screening Information System, Newborn Screening Information System; (3) Reagents: Over 100 diagnostic reagents covering SARS-CoV-2, neonatal screening (G6PD, CAH, CH, PKU), prenatal screening (AFP, β-HCG, uE3), infectious diseases (HIV, hepatitis B/C, TORCH), thyroid function, reproductive hormones, and vitamins. The company operates as the only domestic manufacturer in China specializing in birth defects prevention, with products and services covering more than 20 provinces.
Differentiator
Problem solved
Functional benefit
Brands
- TALENT Series: Time-resolved fluorescence immunoassay analyzer product line including TALENT Time-Resolver Fluorometer, TALENT-I, TALENT II, and TALENT-STAR multi-functional fluorescence analyzer.
- EasyDBS
- COVID-19 Product Portfolio
Products and services
- FH-6000MD Clinical Mass Spectrometry System Clinical mass spectrometry instrument for analyzing biological samples in clinical diagnostic workflows; intended for hospital and clinical laboratory use.
- AutoTRFIA Automated Immunoassay Analyzer Automated time-resolved fluorescence immunoassay (TRFIA) analyzer for high-sensitivity clinical immunoassay testing; intended for clinical laboratories and hospital labs.
- TALENT Series Time-Resolved Fluorescence Immunoassay Analyzers (TALENT-I, TALENT-II, TALENT-STAR) Family of time-resolved fluorescence immunoassay analyzers (TALENT-I, TALENT-II, TALENT-STAR) for high-sensitivity clinical diagnostic testing; intended for clinical and hospital labs.
- EasyDBS 100 / EasyDBS 600 Dry Blood Spot Punchers Automated dry blood spot punchers (EasyDBS 100 and EasyDBS 600) for preparing dried blood spot samples in neonatal screening workflows; intended for screening laboratories and maternal and child health institutions.
- BW 1108 Automated Microplate Washer Automated microplate washer (BW 1108) used as supporting instrumentation in clinical immunoassay workflows; intended for clinical and hospital laboratories.
- Prenatal Screening Risk Assessment Software Software for calculating and reporting prenatal screening risk assessment results; intended for maternal and child health institutions and prenatal screening programs.
- Prenatal Screening Information System Information management system that supports prenatal screening program workflows, data management, and reporting; intended for maternal and child health institutions running prenatal screening.
- Newborn Screening Information System Information management system that supports neonatal screening program workflows, data management, and reporting; intended for screening laboratories and maternal and child health institutions.
- COVID-19 Antigen Rapid Test Kit Colloidal gold-based rapid antigen test kit for detection of SARS-CoV-2 infection; intended for clinical and point-of-care use in COVID-19 screening.
- SARS-CoV-2 IgM/IgG Combo Rapid Test Kit Rapid test kit for simultaneous detection of SARS-CoV-2 IgM and IgG antibodies; intended for clinical serology screening of COVID-19 immune response.
- Neonatal Screening Reagent Kits Reagent kits for newborn screening assays run on Fenghua immunoassay and dry blood spot platforms; intended for neonatal screening laboratories.
- Prenatal Screening Reagent Kits Reagent kits for prenatal screening assays run on Fenghua immunoassay platforms; intended for prenatal screening laboratories and maternal and child health institutions.
- Infectious Disease Reagent Kits Reagent kits for clinical infectious disease testing on Fenghua immunoassay platforms; intended for hospital and clinical laboratories.
- Hormone Analysis Reagent Kits Reagent kits for clinical hormone analysis on Fenghua immunoassay platforms; intended for hospital laboratories and endocrine testing workflows.
Quantifiable outcome
- Detection rate for Down syndrome and neural tube defects >90%, with false positive rate <5%
- +1 more outcomes
Companies that use Fenghua Biological
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Fenghua Biological technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Fenghua Biological partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Fortune 500 Company (unnamed)coreCodevelopment partnership with a Fortune 500 company to create the FH-6000MD triple quadrupole mass spectrometry system specifically designed for the Chinese market. Fenghua contributed local market expertise and application development while the partner provided core mass spectrometry technology platform.
- Southern Medical University (南方医科大学)coreLong-term strategic R&D partnership for joint research and development in clinical diagnostics. Fenghua collaborates with Southern Medical University as part of its broad产学研 (industry-academia-research) cooperation model.
- South China University of Technology (华南理工大学)coreLong-term strategic R&D partnership for joint research and development in clinical diagnostics. Fenghua collaborates with South China University of Technology as part of its产学研 cooperation model.
- National Key Laboratory of Medical Genetics, Central South University (中南大学医学遗传学国家重点实验室)coreLong-term strategic R&D partnership focused on medical genetics research and diagnostic technology development. Fenghua collaborates with this national key laboratory as part of its产学研 cooperation model.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Fenghua Biological competitors and assessment
Company assessmentBroad incumbents
- Abbott Diagnostics: Global IVD leader offering ARCHITECT immunoassay and Alinity platforms that compete directly in prenatal/neonatal screening menus. Overlaps with Fenghua in hepatitis, TORCH, and hormone reagent categories globally.
- Roche Diagnostics: Global IVD incumbent with cobas immunoassay, Elecsys prenatal screening, and mass spectrometry platforms. Competes with Fenghua in prenatal/neonatal screening reagent categories inside China and globally, though at a vastly broader scale.
- Mindray: China's largest medical device and IVD company with a comprehensive immunoassay, hematology, and microbiology portfolio. Competes with Fenghua across Chinese hospital IVD procurement but at vastly greater scale and with a far broader product line.
Direct peers
- Autobio Diagnostics: Major Chinese IVD company offering immunoassay analyzers, microbiology, and clinical chemistry reagents with hospital-channel distribution nationwide. Directly comparable as a domestic Chinese IVD manufacturer competing for the same hospital and clinical lab procurement contracts.
- Shenzhen New Industries Biomedical Engineering (Snibe): China's leading chemiluminescence immunoassay IVD company with a broad reagent menu spanning prenatal, infectious disease, and hormone panels. Comparable as a Chinese-headquartered IVD manufacturer selling immunoassay instruments and matching reagents to hospitals and labs.
- BGI Genomics: Chinese genetic and prenatal diagnostics company offering NIPT and carrier screening tests. Comparable as a Chinese-headquartered prenatal/genetic diagnostics provider competing for the same clinical screening end-market, though BGI is largely a lab service rather than IVD manufacturer.
- Da An Gene (Sun Yat-sen University Da An Gene): Chinese molecular diagnostics and clinical IVD company with strong presence in infectious disease and prenatal screening reagents. Comparable as a domestic Chinese IVD manufacturer with overlapping reagent menu and hospital distribution.
- Revvity (formerly PerkinElmer Life Sciences / Newborn Screening): Global leader in newborn screening through tandem mass spectrometry and immunoassay platforms. Comparable as a dedicated newborn/prenatal screening IVD company that pioneered the same MS/MS-based metabolic screening modality Fenghua entered with the FH-6000MD.
- DiaSorin: Italian specialty IVD company focused on immunodiagnostics and molecular diagnostics, with a notable congenital disease and prenatal/neonatal screening menu. Comparable as a specialized immunoassay IVD player in similar clinical screening niches.
Emerging players
- Hologic: Women's health diagnostics company with prenatal screening assays (e.g., first-trimester risk assessment). Adjacent as a specialty diagnostics player in maternal-fetal screening, though broader franchise is in cytology and molecular.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Fenghua Biological compliance and trust
Trust signalCompliance7 records
Fenghua Biological financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fenghua Biological leadership team
Management profileNumber of profiles
Fenghua Biological funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fenghua Biological M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fenghua Biological
What does Fenghua Biological do?
Fenghua Biological develops, manufactures, and sells clinical diagnostic instruments and matching reagent kits for in vitro diagnostics, including time-resolved fluorescence immunoassay (TRFIA) analyzers, clinical mass spectrometry systems (FH-6000MD), automated dry blood spot punchers, and reagent kits for prenatal screening, neonatal screening, infectious disease testing, and hormone analysis. The portfolio is complemented by software products for prenatal and newborn screening program management and risk assessment. Customers are hospitals, maternal and child health institutions, clinical laboratories, and disease control centers across China.
Is Fenghua Biological a public or private company?
Fenghua Biological is a private company. It is classified as unknown and is currently operating.
When was Fenghua Biological founded?
Fenghua Biological was founded in 1999.
Where is Fenghua Biological based?
Fenghua Biological is headquartered in Guangzhou, China, in the Asia region.
How does Fenghua Biological make money?
Two revenue lines are on record. Clinical Diagnostic Instruments and Reagents are the primary driver. The others are recurring Diagnostic Reagent Sales.
Who are Fenghua Biological's main competitors?
Broad incumbents on record are Abbott Diagnostics, Roche Diagnostics and Mindray. Direct peers are Autobio Diagnostics, Shenzhen New Industries Biomedical Engineering (Snibe), BGI Genomics, Da An Gene (Sun Yat-sen University Da An Gene), Revvity (formerly PerkinElmer Life Sciences / Newborn Screening) and DiaSorin. Hologic is listed as an emerging player.
Does Fenghua Biological have an API?
No public API is recorded for Fenghua Biological.
What industry is Fenghua Biological in?
Fenghua Biological's product category is In Vitro Diagnostics (IVD). Its primary akta.pro industry code is HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD, with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.